Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA

Min Huang, Gilberto De Lima Lopes, Ralph P. Insinga, Thomas Burke, Flavia Ejzykowicz, Ying Zhang, Josephine L. Feliciano

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Aim: This analysis aimed to evaluate the cost-effectiveness of pembrolizumab monotherapy as first-line treatment in advanced non-small-cell lung cancer patients with a programmed death ligand 1 (PD-L1) tumor proportion score ≥1% from a US payer perspective. Materials & methods: A partitioned survival model was developed using efficacy and safety data from the KEYNOTE-042 trial and projected over 20 years. Costs accounted for treatment, toxicity and disease management. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios were reported. Results: Pembrolizumab resulted in an expected gain of 0.60 life years and 0.49 QALYs compared with platinum-based chemotherapy. The incremental cost-effectiveness ratio was US$130,155/QALY. Conclusion: Pembrolizumab is projected to be cost-effective compared with platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer with PD-L1 tumor proportion score ≥1%.

Original languageEnglish (US)
Pages (from-to)1463-1479
Number of pages17
JournalImmunotherapy
Volume11
Issue number17
DOIs
StatePublished - 2019

Keywords

  • advanced NSCLC
  • cost-effectiveness
  • PD-L1-positive
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA'. Together they form a unique fingerprint.

Cite this